Marta Colaneri

Dr. Marta Colaneri

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
MCMarta Colaneri
Marta Colaneri
LBLaura Bogliolo
Laura Bogliolo
PVPietro Valsecchi
Pietro Valsecchi
PSPaolo Sacchi
Paolo Sacchi
VZValentina Zuccaro
Valentina Zuccaro
TFThe Covid Irccs San Matteo Pavia Task Force
The Covid Irccs San Matteo Pavia Task Force
Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19.

30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
ESElena Seminari
Elena Seminari
MCMarta Colaneri
Marta Colaneri
MSMARGHERITA SAMBO
MARGHERITA SAMBO
IGIlaria Gallazzi
Ilaria Gallazzi
AMAngela Di Matteo
Angela Di Matteo
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
The clinical manifestation of COVID-19 can vary from an asymptomatic course to ARDS requiring invasive mechanical ventilation and extracorporeal membrane oxygenation. A kidney transplanted patient infected with SARS CoV-2 infection showed a mild disease despite immune suppression. It is possible that Immunosuppression can "be protective" as the cytokine storm is an important factor in the disease story. Despite the good outcome reported in the present case report, is remains of vital importance the solid organ transplant patients use precautions in order to avoid the infection.

20 September 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MCMarta Colaneri
Marta Colaneri
MFMaria De Filippo
Maria De Filippo
ALAmelia Licari
Amelia Licari
AMAlessia Marseglia
Alessia Marseglia
LMLaura Maiocchi
Laura Maiocchi
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
There is ongoing debate regarding the role of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in asthma exacerbation, and its long-term impact on the lung function of individuals with asthma. In contrast, the potential impact of coronavirus disease 2019 (COVID-19) vaccination on asthma is entirely unexplored. This study examined a challenging case of severe asthma exacerbation in a 28-year-old female following two doses of the mRNA-based vaccine BNT162b2 (Pfizer-BioNTech) at IRCCS Policlinico San Matteo in Pavia, Italy. The patient, a fourth-year resident at the hospital, was vaccinated in early 2021. She was an occasional smoker with a 10-year history of asthma and seasonal allergic rhinitis. She tested negative for SARS-CoV-2 on several molecular swabs and serology tests. After receiving the second dose of vaccine, the patient started to experience worsening of respiratory symptoms. Following several episodes and a severe asthma attack, the patient required treatment with mepolizumab, a biologic drug (interleukin-5) antagonist monoclonal antibody. This single case study is insufficient to draw conclusions about the association between asthma exacerbation and the COVID-19 vaccine. While the cause–effect link between vaccination against SARS-CoV-2 and worsening of asthmatic disease might only be suggested at present, this case is a valuable prompt for further investigation. This is particularly true from the perspective of mass vaccination of adolescents and children currently underway across the globe.

27 May 2025 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
MCMarta Colaneri
Marta Colaneri
GMGiorgia Montrucchio
Giorgia Montrucchio
GSGiovanni Scaglione
Giovanni Scaglione
GMGianpaola Monti
Gianpaola Monti
GTGiovanni Tricella
Giovanni Tricella
LDLidia Dalfino
Lidia Dalfino
Despite preventive measures, ventilator-associated pneumonia (VAP) remains the most common healthcare-associated infection in the intensive care unit (ICU). VAP's striking incidence and impact are a leading cause of morbidity and prolonged ICU stay. This study focused on the characteristics and outcomes of patients diagnosed with ICU-acquired VAPs in Italian ICUs. Data were drawn from the PROSAFE network, a prospective multicentric observational project conducted across 192 Italian ICUs (2014-2023). Clinical data were recorded following the European Centre for Disease Prevention and Control VAP definitions. The incidence rate was estimated, and multivariable logistic regression identified ICU mortality risk factors. The patients admitted to the included ICUs were 402 085. Among 122 430 classified at risk for VAP because of invasive mechanical ventilation (IMV) ≥48 hours, a total of 11 978 VAP cases were identified, corresponding to a prevalence of 9.8%. The incidence rate of VAP was 10.47 cases per 1 000 ventilator days (95% CI: 10.28-10.66). Patients with VAP exhibited prolonged ICU stays (median: 23 days, Q1-Q3: 15-36) and high mortality (30.0%). Microbiological profiling of VAP identified Pseudomonas spp. (21.0%), Staphylococcus aureus (20.2%), and Klebsiella spp. (20.1%) as the predominant pathogens. The logistic regression showed that older age, chronic liver and kidney diseases, multidrug-resistant organisms, and Acinetobacter spp. aetiology and duration of ICU stay before VAP were significantly associated with higher mortality. While confirming the overall high mortality of patients undergoing IMV, our findings highlight the significantly prolonged ICU stay in VAP patients, and the influence of multidrug-resistant organisms on VAP-related mortality. These insights emphasize the necessity for effective and timely preventive strategies, as well as the early identification of VAP aetiology.

3 April 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
DCDario Cattaneo
Dario Cattaneo
MFMarta Fusi
Marta Fusi
LGLucia Galli
Lucia Galli
CGCamilla Genovese
Camilla Genovese
RGRiccardo Giorgi
Riccardo Giorgi
AGAndrea Gori
Andrea Gori
Here, we describe the use of proactive therapeutic drug monitoring (TDM) to individualize the optimal timing of drug injections in 16 adult patients with chronic osteoarticular infections receiving a median of 7 injections of dalbavancin (up to 12 injections in 15 months). Dalbavancin injections were repeated at medians of 39–47 days, with infusion intervals ranging from 26 to 69 days. TDM can facilitates a precise, targeted use of dalbavancin for infections requiring prolonged treatments.

1 July 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MCMarta Colaneri
Marta Colaneri
EGEmanuele Maria Giusti
Emanuele Maria Giusti
CGCamilla Genovese
Camilla Genovese
LGLucia Galli
Lucia Galli
Andrea LombardiAndrea Lombardi
Andrea Lombardi
AGAndrea Gori
Andrea Gori
Mortality of candidemia in coronavirus disease 2019 (COVID-19) patients has not been deeply studied despite evidence suggesting an increased occurrence. We performed a systematic review and meta-analysis to summarize the available evidence about these patients’ mortality and length of stay. Data about the in-hospital, all-cause and 30-day mortality, and length of stay were pooled. Subgroup analyses were performed to assess sources of heterogeneity. Twenty-six articles out of the 1915 records retrieved during the search were included in this review. The pooled in-hospital mortality was 62.62% (95% CI, 54.77% to 69.86%), while the mortality in intensive care unit (ICU) was 66.77% (95% CI, 57.70% to 74.75%). The pooled median in-hospital length of stay was 30.41 (95% CI, 12.28 to 48.55) days, while the pooled median length of stay in the ICU was 28.28 (95% CI, 20.84 to 35.73) days. The subgroup analyses did not identify the sources of heterogeneity in any of the analyses. Our results showed high mortality in patients with candidemia and COVID-19, suggesting the need to consider screening measures to prevent this life-threatening condition.